ESPR Esperion Therapeutics Inc

Esperion to Present at JPMorgan Healthcare Conference ANN ARBOR, Mich., Jan. 9 /PRNewswire-FirstCall/ -- Esperion Therapeutics, Inc. , a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies to improve the treatment of cardiovascular disease, today announced that President and CEO Roger S. Newton, Ph.D. will present at the JPMorgan Healthcare Conference in San Francisco on Tuesday, January 13, 2004 at 9:00 a.m. (PST). Investors and others may access a live audio webcast of the presentation at http://equityconferences.jpmorgan.com/ . An audio replay of the Esperion presentation may be accessed at http://equityconferences.jpmorgan.com/ until February 1, 2004. Esperion Therapeutics Esperion Therapeutics, Inc. discovers and develops pharmaceutical products for the treatment of cardiovascular disease. Esperion intends to commercialize a novel class of drugs that focuses on a new treatment approach called "HDL Therapy," which is based on the Company's understanding of high- density lipoprotein, or HDL, function. HDL is the primary facilitator of the reverse lipid transport, or RLT, pathway by which excess cholesterol and other lipids are removed from artery walls and other tissues and are transported to the liver for elimination from the body. Esperion's goal is to develop drugs that exploit the beneficial functions of HDL within the RLT pathway. Esperion currently has four product candidates in clinical development. Esperion is listed on the Nasdaq National Market under the symbol "ESPR." Company Amy Cannon Contact: Manager, Corporate Communications Esperion Therapeutics, Inc. (734) 222-1801 DATASOURCE: Esperion Therapeutics, Inc. CONTACT: Amy Cannon, Manager, Corporate Communications of Esperion Therapeutics, Inc., +1-734-222-1801, Web site: http://www.esperion.com/ http://equityconferences.jpmorgan.com/

Copyright